| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/06/2011 | US20110002859 Chewing gum containing eucalyptus extract |
| 01/06/2011 | US20110002858 Oral compositions for absorption of phosphorous compounds |
| 01/06/2011 | US20110002857 Oleaginous pharmaceutical and cosmetic foam |
| 01/06/2011 | US20110002855 Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| 01/06/2011 | US20110002854 Use of Francisella Tularensis For Prevention and Treatment of Allergic Airway Disorders |
| 01/06/2011 | US20110002851 Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases |
| 01/06/2011 | US20110002844 Stabilization of macromolecular membranes |
| 01/06/2011 | CA2803987A1 Non-sedating antihistamine injection formulations and methods of use thereof |
| 01/06/2011 | CA2803672A1 Liposomes for pulmonary administration |
| 01/06/2011 | CA2767129A1 Compositions and methods for silencing apolipoprotein b |
| 01/06/2011 | CA2767127A1 Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| 01/06/2011 | CA2766884A1 Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
| 01/06/2011 | CA2766834A1 Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| 01/06/2011 | CA2766803A1 Laboratory animal pulmonary dosing device |
| 01/06/2011 | CA2766530A1 Apparatus and methods for implanting particulate ocular implants |
| 01/06/2011 | CA2766482A1 Drug delivery system comprising polyoxazoline and a bioactive agent |
| 01/06/2011 | CA2766345A1 Pharmaceutical ophthalmological liquid compositions containing propionic acid derivatives as a preservative |
| 01/06/2011 | CA2766269A1 Method for improving bioavailability of latanoprost |
| 01/06/2011 | CA2766202A1 Pharmaceutical tablet containing a liquid filled capsule |
| 01/06/2011 | CA2766067A1 3-cyanoquinoline tablet formulations and uses thereof |
| 01/06/2011 | CA2765920A1 Antimicrobial material |
| 01/06/2011 | CA2765852A1 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections |
| 01/06/2011 | CA2764181A1 Stable shellac enteric coating formulation for nutraceutical and pharmaceutical dosage forms |
| 01/06/2011 | CA2753290A1 Topical skin treatment kits |
| 01/05/2011 | EP2270007A1 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| 01/05/2011 | EP2269662A1 Method and solder for strong connection of two surfaces |
| 01/05/2011 | EP2269653A1 Composition for stabilizing -blocker, and transdermally absorbable preparation comprising the composition |
| 01/05/2011 | EP2269652A1 Composition for external application to skin |
| 01/05/2011 | EP2269648A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 01/05/2011 | EP2269647A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 01/05/2011 | EP2269645A2 Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
| 01/05/2011 | EP2269638A2 Vaccine compositions comprising virosomes and a saponin adjuvant |
| 01/05/2011 | EP2269637A1 Influenza Vaccine |
| 01/05/2011 | EP2269631A2 Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics |
| 01/05/2011 | EP2269613A2 Solid orald dosage form comprising a combination of metformin and glibenclamide |
| 01/05/2011 | EP2269608A2 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| 01/05/2011 | EP2269606A2 Transdermal analgesic systems having reduced abuse potential |
| 01/05/2011 | EP2269605A2 Methylphenidate Modified Release Formulations |
| 01/05/2011 | EP2269599A1 Chemically stable compositions of 4-hydroxy tamoxifen and their therapeutical applications |
| 01/05/2011 | EP2269595A1 Titratable dosage transdermal delivery system |
| 01/05/2011 | EP2269593A1 Transdermally absorbable preparation |
| 01/05/2011 | EP2269592A1 Pharmaceutical composition of micronised progesterone and its use |
| 01/05/2011 | EP2269591A2 Improved pharmaceutical formulations |
| 01/05/2011 | EP2269590A2 Ion binding polymers and uses thereof |
| 01/05/2011 | EP2269589A2 Ion binding polymers and uses thereof |
| 01/05/2011 | EP2269588A1 Medicinal tablet with prolonged release of the active agent |
| 01/05/2011 | EP2269587A1 Controlled release hydrocodone formulations |
| 01/05/2011 | EP2269586A1 Pharmaceutical composition comprising desloratadine |
| 01/05/2011 | EP2269585A2 Once-a-day oxycodone formulations |
| 01/05/2011 | EP2269584A1 Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
| 01/05/2011 | EP2269583A1 Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
| 01/05/2011 | EP2269582A2 Multiparticulates of preferably an opioid, and method of manufacturing using extrusion |
| 01/05/2011 | EP2269581A1 Improvements relating to biocidal compositions |
| 01/05/2011 | EP2269580A2 Compositions comprising camptothecins in microspheres |
| 01/05/2011 | EP2269579A2 Tamper-resistant products for opioid delivery |
| 01/05/2011 | EP2269578A2 Generation of Therapeutic Microfoam |
| 01/05/2011 | EP2269577A2 Injectable suspensions having improved injectability properties |
| 01/05/2011 | EP2269576A2 A Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 01/05/2011 | EP2269575A1 Method for improving bioavailability of latanoprost |
| 01/05/2011 | EP2269574A2 Implants for administering substances and methods of producing implants |
| 01/05/2011 | EP2269573A1 Zinc preservative composition and method of use |
| 01/05/2011 | EP2269572A1 Polymeric compositions comprising crystalline therapeutic agents and their preparations |
| 01/05/2011 | EP2268299A1 Compositions and method for reducing scar formation in wound healing |
| 01/05/2011 | EP2268288A2 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| 01/05/2011 | EP2268283A2 Oral modified-release formulations containing thiazepines |
| 01/05/2011 | EP2268282A1 Liquid formulation for deferiprone with palatable taste |
| 01/05/2011 | EP2268271A1 Hand sanitizing patch |
| 01/05/2011 | EP2268270A2 Improved formulations for poorly permeable active pharmaceutical ingredients |
| 01/05/2011 | EP2268269A2 Sulfoalkyl ether cyclodextrin compositions |
| 01/05/2011 | EP2268268A2 Orally disintegrating compositions of rhein or diacerein |
| 01/05/2011 | EP2268267A2 Dry transglutaminase composition |
| 01/05/2011 | EP2268266A2 Process for obtaining powder compositions of orlistat to be filled into a capsule |
| 01/05/2011 | EP2268265A2 Compositions for site-specific delivery of imatinib and methods of use |
| 01/05/2011 | EP2268264A1 Cross-linked polymer matrix, in particular for administering active ingredients |
| 01/05/2011 | EP2268263A1 Improved topical ophthalmic compositions |
| 01/05/2011 | EP2268262A2 Medical device |
| 01/05/2011 | EP2268261A2 Multi-mode communication ingestible event markers and systems, and methods of using the same |
| 01/05/2011 | EP2268160A1 Emulsions including a peg-derivative of tocopherol |
| 01/05/2011 | EP2178504B1 Preservative-free prostaglandin-based ophthalmic solution |
| 01/05/2011 | EP2170368B1 Liquid protein formulations comprising gdf-5 for use at elevated temperatures |
| 01/05/2011 | EP2076250B1 Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations |
| 01/05/2011 | EP1789026B1 Method for systemic bio-correction of an organism |
| 01/05/2011 | EP1771180B2 Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase |
| 01/05/2011 | EP1765356B2 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase |
| 01/05/2011 | EP1763338B1 Oral sustained release formulation of tedisamil with gastric retention properties |
| 01/05/2011 | EP1750862B1 Pharmaceutical composition containing irbesartan |
| 01/05/2011 | EP1750667B1 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 01/05/2011 | EP1725233B1 Pharmaceutical composition comprising sns-595 and uses thereof |
| 01/05/2011 | EP1699445B1 Collagen and polysaccharide-based coating composition |
| 01/05/2011 | EP1680110B1 Once daily dosage forms of trospium |
| 01/05/2011 | EP1663315B1 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 01/05/2011 | EP1478406B1 Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
| 01/05/2011 | EP1465637B1 25-hydroxy vitamin d3 compositions |
| 01/05/2011 | EP1365778B1 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 01/05/2011 | EP1128814B1 Aerosols comprising nanoparticle drugs |
| 01/05/2011 | DE102010030546A1 Dental care chewing gum, useful for reduction of bacterial count in the oral cavity and maintaining the dental and oral hygiene, comprises silver |
| 01/05/2011 | CN201692349U Amlodipine polypharmacy valsartan capsule tablet |
| 01/05/2011 | CN1951952B Triterpene compound for preparing drug for treating cranial glia tumour |
| 01/05/2011 | CN1943654B A Chinese traditional medicinal composition and its preparation method |
| 01/05/2011 | CN1905866B Tulobuterol adhesive patch |